Harmony Biosciences (HRMY) Tops Q1 EPS by 25c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $37 at Raymond James
April 30, 2024 12:17 PM EDTRaymond James analyst Danielle Brill raised the price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) to $37.00 (from $34.00) while maintaining a Outperform rating.
The analyst comments "Wakix 1Q sales of $154.6M (-8.2% q/q) slightly beat our $152.9M estimate (vs consensus $154.7M), and FY24 revenue guidance of... More
